C-Kit expression is rate-limiting for stem cell factor-mediated disease progression in adenoid cystic carcinoma of the salivary glands

Translational Oncology

Volumn 7, Issue 5, 2014, Pages 537-545

  Phuchareon, Janyaporn ^a,b   van Zante, Annemieke ^a   Overdevest, Jonathan B ^a   McCormick, Frank ^b   Eisele, David W ^a,b   Tetsu, Osamu ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; GENOMIC DNA; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; STEM CELL FACTOR RECEPTOR;

ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIMERIZATION; DISEASE COURSE; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; MALE; METASTASIS; MIDDLE AGED; MRNA EXPRESSION ASSAY; MUTATIONAL ANALYSIS; ONCOGENE C KIT; OVERALL SURVIVAL; PERINEURAL INVASION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SALIVARY GLAND; TUMOR MICROENVIRONMENT; VERY ELDERLY;

EID: 84915767556     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2014.07.006     Document Type: Article

References (32)

1. Spiro RH, Huvos AG, and Strong EW (1974). Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 128, 512–520.
2. Phuchareon J, Ohta Y, Woo JM, Eisele DW, and Tetsu O (2009). Genetic profiling reveals cross-contamination andmisidentification of 6 adenoid cystic carcinoma cell lines: ACC2, ACC3, ACCM, ACCNS, ACCS and CAC2. PLoS One 4, e6040. http://dx.doi.org/10.1371/journal.pone.0006040.
3. Tetsu O, Phuchareon J, Chou A, Cox DP, Eisele DW, and Jordan RC (2010). Mutations in the c-Kit gene disrupt mitogen-activated protein kinase signaling during tumor development in adenoid cystic carcinoma of the salivary glands. Neoplasia 12, 708–717.
4. Laurie SA and Licitra L (2006). Systemic therapy in the palliative management of advanced salivary gland cancers. J Clin Oncol 24, 2673–2678.
5. Liu J, Shao C, Tan ML, Mu D, Ferris RL, and Ha PK (2012). Molecular biology of adenoid cystic carcinoma. Head Neck 34, 1665–1677.
6. Lennartsson J and Ronnstrand L (2012). Stem cell factor receptor/c-Kit: From basic science to clinical implications. Physiol Rev 92, 1619–1649.
7. Holst VA, Marshall CE, Moskaluk CA, and Frierson Jr HF (1999). KIT protein expression and analysis of c-Kit gene mutation in adenoid cystic carcinoma. Mod Pathol 12, 956–960.
8. Mino M, Pilch BZ, and Faquin WC (2003). Expression of KIT (CD117) in neoplasms of the head and neck: An ancillary marker for adenoid cystic carcinoma. Mod Pathol 16, 1224–1231.
9. Negri T, Tamborini E, Dagrada GP, Greco A, Staurengo S, Guzzo M, Locati LD, Carbone A, Pierotti MA, and Licitra L, et al (2008). TRK-a, HER-2/neu, and KIT expression/activation profiles in salivary gland carcinoma. Transl Oncol 1, 121–128.
10. Freier K, Flechtenmacher C, Walch A, Devens F, Muhling J, Lichter P, Joos S, and Hofele C (2005). Differential KIT expression in histological subtypes of adenoid cystic carcinoma (ACC) of the salivary gland. Oral Oncol 41, 934–939.
11. Moskaluk CA, Frierson Jr HF, El-Naggar AK, and Futreal PA (2010). C-kit gene mutations in adenoid cystic carcinoma are rare. Mod Pathol 23, 905–906.
12. Bell D, Roberts D, Kies M, Rao P, Weber RS, and El-Naggar AK (2010). Cell type-dependent biomarker expression in adenoid cystic carcinoma: biologic and therapeutic implications. Cancer 116, 5749–5756.
13. Alcedo JC, Fabrega JM, Arosemena JR, and Urrutia A (2004). Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: Report of two successfully treated cases. Head Neck 26, 829–831.
14. Faivre S, Raymond E, Casiraghi O, Temam S, and Berthaud P (2005). Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23, 6271–6273.
15. Hotte SJ, Winquist EW, Lamont E, MacKenzie M, Vokes E, Chen EX, Brown S, Pond GR, Murgo A, and Siu LL (2005). Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-Kit: A Princess Margaret Hospital phase II consortium study. J Clin Oncol 23, 585–590.
16. Alexeev V and Yoon K (2006). Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 126, 1102–1110.
17. Hitre E, Budai B, Takacsi-Nagy Z, Rubovszky G, Toth E, Remenar E, Polgar C, and Lang I (2010). Cetuximab and platinum-based chemoradio- or chemotherapy of patients with epidermal growth factor receptor expressing adenoid cystic carcinoma: a phase II trial. Br J Cancer 109, 1117–1122.
18. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, and Blumenschein GR (2014). A phase II study ofGefitinib in patients with advanced salivary gland cancers. Head Neck. http://dx.doi.org/10.1002/hed.23647.
19. Cohen J (1992). A power primer. Psychol Bull 112, 155–159.
20. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, and Walter P (2008). Molecular biology of the cell. 5th ed. New York, NY: Garland Sicence; 2008 879–964.
21. Wiesner C, Nabha SM, Dos Santos EB, Yamamoto H, Meng H, Melchior SW, Bittinger F, Thüroff JW, Vessella RL, and Cher ML, et al (2008). C-kit and its ligand stem cell factor: Potential contribution to prostate cancer bone metastasis. Neoplasia 10, 996–1003.
22. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'hern R, Nerurkar A, Osin P, Smith IE, and Dowsett M (2010). Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 12, R76. http://dx.doi.org/10.1186/bcr2719.
23. Zhou Q, Chang H, Zhang H, Han Y, and Liu H (2012). Increased numbers of P63- positive/CD117-positive cells in advanced adenoid cystic carcinoma give a poorer prognosis. Diagn Pathol 7, 119. http://dx.doi.org/10.1186/1746-1596-7-119.
24. Sandvik AK, Alsberg BK, Norsett KG, Yadetie F, Waldum HL, and Laegreid A (2006). Gene expression analysis and clinical diagnosis. Clin Chim Acta 363, 157–164.
25. Finn WG (2007). Diagnostic pathology and laboratory medicine in the age of “omics”: A paper from the 2006 William Beaumont Hospital Symposium on Molecular Pathology. J Mol Diagn 9, 431–436.
26. Persson M, Andren Y, Mark J, Horlings HM, Persson F, and Stenman G (2009). Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 106, 18740–18744.
27. Bell D, Roberts D, Karpowicz M, Hanna EY, Weber RS, and El-Naggar AK (2011). Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma. Cancer Biol Ther 12, 569–573.
28. West RB, Kong C, Clarke N, Gilks T, Lipsick JS, Cao H, Kwok S, Montgomery KD, Varma S, and Le QT (2011). MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 35, 92–99.
29. Mitani Y, Li J, Rao PH, Zhao YJ, Bell D, Lippman SM, Weber RS, Caulin C, and El-Naggar AK (2010). Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance. Clin Cancer Res 16, 4722–4731.
30. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, and Al-Batran SE, et al (2012). One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307, 1265–1272.
31. Edris B, Willingham SB, Weiskopf K, Volkmer AK, Volkmer JP, Mühlenberg T, Montgomery KD, Contreras-Trujillo H, Czechowicz A, and Fletcher JA, et al (2013). Anti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growth. Proc Natl Acad Sci U S A 110, 3501–3506.
32. Lebron MB, Brennan L, Damoci CB, Prewett MC, O'Mahony M, Duignan IJ, Credille KM, DeLigio JT, Starodubtseva M, and Amatulli M, et al (2014). A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth. Cancer Biol Ther 15, 1208–1218.